WASHINGTON − A federal appeals court on Wednesday said it would limit access to the abortion pill mifepristone, ruling that the Food and Drug Administration had overstepped its authority with a series of actions that made it far easier for Americans to obtain the drug, such as allowing prescriptions to be filled by mail.
But the ruling appeared unlikely to have an immediate impact on access to the drug because of an earlier Supreme Court decision that paused changes to the status quo. The appeals court ruling sets up another showdown at the Supreme Court over access to the drug.
The ruling from the three-judge panel of the New Orleans-based 5th U.S. Circuit Court of Appeals, all three of whom were nominated by Republican presidents, was the latest step in what has turned into a months long legal drama over mifepristone. The fight over the drug took on added significance as conservatives state ban abortion in response to the Supreme Court’s decision last year to overturn Roe v. Wade.
The Biden administration is all but certain to appeal the decision to the Supreme Court.
In April, the high court allowed full access to mifepristone while the case played out in lower courts, maintaining the status quo from before the lawsuit was filed. That short-term “stay,” which doesn’t necessarily signal how the court will rule on the underlying merits of the case, remains in place while the appeal of the 5th Circuit’s decision unfolds.
Medication abortion accounts for about half of all U.S. abortions, and a wide array of government agencies and outside experts have said the drug is safer than common drugs such as Tylenol and Viagra. But the anti-abortion groups challenging the drug questioned those studies and argued that the FDA didn’t follow its own protocols and ignored contrary data as it expedited the drug’s approval.
Medication abortion accounts for about half of all U.S. abortions, and a wide array of government agencies and outside experts have said the drug is safer than common drugs such as Tylenol and Viagra. But the anti-abortion groups challenging the drug questioned those studies and argued that the FDA didn’t follow its own protocols and ignored contrary data as it expedited the drug’s approval.
Timeline: How the mifepristone battle got here
The legal rollercoaster began in early April when a pair of federal court rulings plunged the fate of mifepristone into uncertainty. One of those rulings, from U.S. District Judge Matthew Kacsmaryk on April 7, effectively invalidated the FDA’s 23-year-old approval for the drug. Days later, the 5th Circuit sided with the Biden administration on the drug’s approval but let stand the parts of Kacsmaryk’s ruling that halted efforts to expand access to the drug.
Among the moves to expand access: In 2016, the FDA allowed pregnant people to take the drug three weeks longer into a pregnancy. The agency allowed pharmacists to prescribe the drug instead of just doctors. In 2019, the FDA approved a generic version of the drug. In 2021, during the COVID-19 pandemic, it allowed mifepristone to be dispensed through the mail. The agency formalized that mail-order decision earlier this year.
Tracker:Race, religion and debt: Here are the biggest cases pending at the Supreme Court
Other suits:With eyes on Texas mifepristone case, 2 other abortion pill lawsuits ‘flying under the radar’
Then, on April 21, the Supreme Court put the lower court rulings on pause while the case continued. The appeals court heard arguments on May 17, signaling that they were prepared to limit access to the drug.
Safety vs. process: What the case is about
As the mifepristone case has ricocheted through the courts, medical associations and health experts have pointed to the drug’s decades-long safety record and studies showing it to be safer than common drugs such as Tylenol and Viagra. The Department of Health and Human Services, the American Medical Association and the American College of Obstetricians and Gynecologists call mifepristone safe and effective for abortion and miscarriage care.
The anti-abortion groups challenging the drug have questioned those studies and say the FDA didn’t follow its own protocols and ignored contrary data as it expedited the drug’s approval. The groups claim that the expedited procedure the FDA used to approve mifepristone was supposed to be used only for drugs treating an “illness.”
Other drugs:‘No drug is safe’: Mifepristone court battle could threaten access to other FDA-approved drugs
Bio:Mifepristone: Who is Judge Matthew Kacsmaryk and why was the abortion pill case in his court?
But the real fight is about access to abortion as the groups challenging the drug made clear in their arguments to the appeals courts. The FDA’s approval of mail-order abortion drugs, the group said, “subvert the promise” of the Supreme Court’s decision last year to overturn Roe v. Wade, empowering states to decide whether to ban abortions. Those state decisions, the group said, are “rendered meaningless by FDA’s mail-order abortion scheme.”
The Biden administration, not surprisingly, sees it differently. It argued approval was based on clinical trials involving more than 2,500 people and that the drug’s decades long use by over 5 million Americans underscores its safety. Allowing courts to overturn FDA drug approvals “without regard for science or evidence,” it said, would add an intolerable dose of politics to the nation’s pharmaceutical system.
